However, several recent studies have shown that targeting the high-affinity trimeric IL-2R may be beneficial in cancer immunotherapy and that CD25-biased IL-2 agonists21 22 are more effective antitumor agents in comparison to CD25-blocking IL-2 agonists. The gene discussed is IL2RA; the disease is cancer.